KR102788029B1 - 인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체 - Google Patents

인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체 Download PDF

Info

Publication number
KR102788029B1
KR102788029B1 KR1020217023541A KR20217023541A KR102788029B1 KR 102788029 B1 KR102788029 B1 KR 102788029B1 KR 1020217023541 A KR1020217023541 A KR 1020217023541A KR 20217023541 A KR20217023541 A KR 20217023541A KR 102788029 B1 KR102788029 B1 KR 102788029B1
Authority
KR
South Korea
Prior art keywords
antibody
antigen
binding fragment
monoclonal antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217023541A
Other languages
English (en)
Korean (ko)
Other versions
KR20210119404A (ko
Inventor
올가 블라디미로브나 브리타노바
드미트리 보리소비치 스테라비아로프
안나 발렌티노브나 이스트라트바
알렉세이 콘스탄티노비치 미소린
티모페이 알렉산드로비치 네만킨
마리아 알렉산드로프나 셰멜레바
안나 콘스탄티노브나 블라디미로바
아리나 비탈레브나 애니키나
로만 알렉세예비치 이바노프
드미트리 발렌티노비치 모로조프
파벨 안드리비치 야코프레브
세르게이 아나톨리에비치 루꺄노프
Original Assignee
조인트 스탁 컴퍼니 “바이오케드”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조인트 스탁 컴퍼니 “바이오케드” filed Critical 조인트 스탁 컴퍼니 “바이오케드”
Publication of KR20210119404A publication Critical patent/KR20210119404A/ko
Application granted granted Critical
Publication of KR102788029B1 publication Critical patent/KR102788029B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217023541A 2018-12-25 2019-12-24 인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체 Active KR102788029B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018146031A RU2712251C1 (ru) 2018-12-25 2018-12-25 Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
RU2018146031 2018-12-25
PCT/RU2019/050258 WO2020091635A2 (ru) 2018-12-25 2019-12-24 Гуманизированные антитела против участка бета цепи 9-го семейства trbv9 ткр человека, и способы их применения

Publications (2)

Publication Number Publication Date
KR20210119404A KR20210119404A (ko) 2021-10-05
KR102788029B1 true KR102788029B1 (ko) 2025-03-31

Family

ID=69184123

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217023541A Active KR102788029B1 (ko) 2018-12-25 2019-12-24 인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체
KR1020217023568A Pending KR20220131489A (ko) 2018-12-25 2020-02-20 인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217023568A Pending KR20220131489A (ko) 2018-12-25 2020-02-20 인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체

Country Status (25)

Country Link
US (1) US12227572B2 (https=)
EP (1) EP3907239A4 (https=)
JP (1) JP2022532274A (https=)
KR (2) KR102788029B1 (https=)
CN (2) CN113646333B (https=)
AR (1) AR117734A1 (https=)
AU (1) AU2020204492A1 (https=)
BR (1) BR112021012555A2 (https=)
CA (2) CA3127767A1 (https=)
CL (1) CL2021001705A1 (https=)
CO (2) CO2021008218A2 (https=)
CR (1) CR20210354A (https=)
EA (1) EA202191813A1 (https=)
EC (1) ECSP21046333A (https=)
IL (1) IL284370A (https=)
JO (1) JOP20210169B1 (https=)
MA (1) MA53689B1 (https=)
MX (1) MX2021007719A (https=)
MY (1) MY205967A (https=)
PE (1) PE20220217A1 (https=)
PH (2) PH12021551775A1 (https=)
RU (1) RU2712251C1 (https=)
SG (1) SG11202106975VA (https=)
WO (2) WO2020091635A2 (https=)
ZA (1) ZA202104357B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
CN116867519A (zh) * 2020-12-01 2023-10-10 约翰斯霍普金斯大学 治疗t细胞癌症的方法和材料
CN116510006A (zh) * 2022-01-31 2023-08-01 拜奥卡德联合股份公司 抗trbv9抗体的药物组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006758A1 (en) 1988-12-15 1990-06-28 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t cell antigen receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
CN102459643B (zh) 2009-06-25 2016-06-01 弗雷德哈钦森癌症研究中心 检测获得性免疫的方法
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006758A1 (en) 1988-12-15 1990-06-28 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t cell antigen receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clinical& Experimental Immunology, Vol. 134, No. 1, pp. 92-97 (2003)

Also Published As

Publication number Publication date
WO2020091635A3 (ru) 2020-10-22
JP2022532274A (ja) 2022-07-14
CO2021008218A2 (es) 2021-07-30
EP3907239A2 (en) 2021-11-10
PE20220217A1 (es) 2022-02-02
CA3124813A1 (en) 2020-07-02
JOP20210169B1 (ar) 2025-10-01
PH12021551532A1 (en) 2022-02-28
US20220112286A1 (en) 2022-04-14
ZA202104357B (en) 2022-09-28
RU2712251C1 (ru) 2020-01-27
CN114144432A (zh) 2022-03-04
MA53689A1 (fr) 2022-06-30
WO2020139175A3 (ru) 2020-10-29
WO2020091635A2 (ru) 2020-05-07
ECSP21046333A (es) 2021-07-30
CA3127767A1 (en) 2020-05-07
CN113646333A (zh) 2021-11-12
PH12021551775A1 (en) 2022-05-23
US12227572B2 (en) 2025-02-18
MY205967A (en) 2024-11-21
JOP20210169A1 (ar) 2023-01-30
EA202191813A1 (ru) 2021-10-07
SG11202106975VA (en) 2021-07-29
IL284370A (en) 2021-08-31
KR20210119404A (ko) 2021-10-05
BR112021012555A2 (pt) 2021-09-14
CR20210354A (es) 2021-12-20
CO2021009689A2 (es) 2021-08-09
TW202039574A (zh) 2020-11-01
WO2020139175A2 (ru) 2020-07-02
CN113646333B (zh) 2025-04-08
MX2021007719A (es) 2022-03-25
AU2020204492A1 (en) 2021-08-12
CL2021001705A1 (es) 2022-01-28
EP3907239A4 (en) 2022-10-05
AR117734A1 (es) 2021-08-25
KR20220131489A (ko) 2022-09-28
MA53689B1 (fr) 2023-03-31

Similar Documents

Publication Publication Date Title
KR102788029B1 (ko) 인간 trbv9의 베타 쇄 영역에 대한 단일클론 항체
CN113692412B (zh) 特异性地结合人trbv9的单克隆抗体
KR102867660B1 (ko) 단일클론 항체 및 그 이용 방법
US12528868B2 (en) CD1a antibodies and uses thereof
HK40070180A (en) Monoclonal antibodies against the beta chain region of human trbv9
HK40063875B (zh) 针对人TRBV9的β链区域的单克隆抗体
HK40063875A (en) Monoclonal antibodies against the beta chain region of human trbv9
HK40064423A (en) Monoclonal antibodies that bind specifically to human trbv9
EA041932B1 (ru) Моноклональные антитела, которые специфически связываются с участком бета цепи семейства trbv-9 т-клеточного рецептора человека, и способы их применения
HK40064423B (zh) 特异性地结合人trbv9的单克隆抗体
HK40039968A (en) Monoclonal antibodies and methods for using same
HK40039968B (zh) 单克隆抗体及其使用方法
EA041880B1 (ru) Моноклональные антитела и способы их применения
EA042982B1 (ru) Моноклональные антитела против участка бета-цепи trbv9 человека

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210723

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210826

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240321

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250220

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250325

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250325

End annual number: 3

Start annual number: 1

PG1601 Publication of registration